169 related articles for article (PubMed ID: 23806325)
21. Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.
Chen X; Zhou X; Li X; Tang J; Hu X; Wang J; Xu C
Cell Biochem Biophys; 2014 Nov; 70(2):1453-7. PubMed ID: 25005770
[TBL] [Abstract][Full Text] [Related]
22. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
[TBL] [Abstract][Full Text] [Related]
23. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Clin Exp Rheumatol; 2010; 28(6):880-3. PubMed ID: 21122270
[TBL] [Abstract][Full Text] [Related]
24. Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Miranda-Filloy JA; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2009; 27(3):452-8. PubMed ID: 19604438
[TBL] [Abstract][Full Text] [Related]
25. The effect of anti-TNF treatment on osteoblastogenesis in ankylosing spondylitis: the number of circulating osteoblast-lineage cells in peripheral blood decreased after infliximab therapy in patients with ankylosing spondylitis.
Kwon SR; Jung KH; Lim MJ; Son MJ; Choi BH; Park SG; Park W
Clin Exp Rheumatol; 2017; 35(5):837-843. PubMed ID: 28375831
[TBL] [Abstract][Full Text] [Related]
26. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
[TBL] [Abstract][Full Text] [Related]
27. [The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study].
Bunchuk NV; Rumiantseva OA; Loginova EIu; Bochkova AG; Storozhakov GI; Ettinger OA; Kosiura SD; Kamalova RG; Valishina LM
Ter Arkh; 2010; 82(10):41-6. PubMed ID: 21341463
[TBL] [Abstract][Full Text] [Related]
28. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
Rebelo A; Leite S; Cotter J
BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
[TBL] [Abstract][Full Text] [Related]
29. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
[TBL] [Abstract][Full Text] [Related]
30. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
[TBL] [Abstract][Full Text] [Related]
31. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
[TBL] [Abstract][Full Text] [Related]
33. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; de Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2009; 27(2):222-8. PubMed ID: 19473561
[TBL] [Abstract][Full Text] [Related]
34. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab for the treatment of ankylosing spondylitis.
Sieper J; Rudwaleit M; Braun J
Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.
Appel H; Janssen L; Listing J; Heydrich R; Rudwaleit M; Sieper J
Arthritis Res Ther; 2008; 10(5):R125. PubMed ID: 18945353
[TBL] [Abstract][Full Text] [Related]
37. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters.
Kemény-Beke Á; Gesztelyi R; Bodnár N; Zsuga J; Kerekes G; Zsuga M; Biri B; Kéki S; Szodoray P; Berta A; Szekanecz Z; Szántó S
Joint Bone Spine; 2011 Mar; 78(2):184-7. PubMed ID: 20620092
[TBL] [Abstract][Full Text] [Related]
38. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; De Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2008; 26(2):311-6. PubMed ID: 18565254
[TBL] [Abstract][Full Text] [Related]
39. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
Agirbasli M; Inanc N; Baykan OA; Direskeneli H
Clin Exp Rheumatol; 2006; 24(5):580-3. PubMed ID: 17181930
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity.
Papadakis JA; Sidiropoulos PI; Karvounaris SA; Vrentzos GE; Spanakis EK; Ganotakis ES; Kritikos HD; Mikhailidis DP; Boumpas DT
Clin Exp Rheumatol; 2009; 27(2):292-8. PubMed ID: 19473571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
